LARA MEJIA, LUIS ANTONIO
ESPECIALIDAD MÉDICA · Nivel C
Desde 2021 es Physician and Clinical Researcher en Instituto Nacional de Cancerología
Dr. Luis Lara is a medical oncologist and currently serves as the Head of the Pharmacological Research Center (CIF) at...
Dr. Luis Lara is a medical oncologist and currently serves as the Head of the Pharmacological Research Center (CIF) at the National Cancer Institute (INCan) in Mexico City. His professional and academic work is focused on clinical and translational research in thoracic oncology, with particular emphasis on non-small cell lung cancer (NSCLC), ALK- and EGFR-driven malignancies, and the exploration of novel therapeutic strategies in high-risk populations.
Índice de visibilidad digital v1.0 · Mide qué tan completo está el perfil, no la calidad académica. Escala: 0–39 incompleto · 40–79 intermedio · 80–100 completo. ¿Cómo se calcula? · ¿Te falta un dato? Avísanos
| Nombre | LUIS ANTONIO LARA MEJIA |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | ESPECIALIDAD MÉDICA |
| Disciplina | ONCOLOGÍA |
| Especialidad | ONCOLOGIA |
| CVU | 518994 |
| Institución | |
|---|---|
| Tipo de institución | Pública |
| Dependencia | DIVISION DE INVESTIGACION CLINICA |
| Entidad | CIUDAD DE MEXICO |
| Nivel | C |
| Vigencia | Inicio: 01/01/2024 |
| Fin: 31/12/2027 |
Evolución en el SNII
- Candidato: 2024–2026
Publicaciones ORCID
- 2025
- Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial Nature Communications
- Preclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma Marine Drugs
- Elucidating the Role of EGFR L858R in Brain Metastasis Among Patients with Advanced NSCLC Undergoing TKI Therapy Clinical Lung Cancer · ISSN 1525-7304
- 2024
- EGFR plus MET targeted therapies for overcoming treatment resistance in EGFR mutant NSCLC. A Case Report Oncology Research and Treatment · ISSN 2296-5270
- Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC Journal of Experimental & Clinical Cancer Research · ISSN 1756-9966
- 2023
- Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI Cancer Biomarkers · ISSN 1875-8592
- Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer Frontiers in Oncology · ISSN 2234-943X
- Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer. Journal of Thoracic Oncology · ISSN 1556-0864
- Obesity paradox and lung cancer, metformin-based therapeutic opportunity? Oncotarget · ISSN 1949-2553
- Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer Frontiers in Oncology · ISSN 2234-943X
